Truvada, a brand name for the generic combination of emtricitabine and tenofovir disoproxil fumarate has now been given the green light as the first pre-exposure prophylaxis for HIV. The generic ingredients are themselves already used in HIV treatment in drugs such as Emtriva (emtricitabine), Viread (tenofovir) and Atripla (emtricitabine/ tenofovir/ efavirenz).
Truvada itself was previously approved to be used in combination with other antiretroviral agents for the treatment of HIV-infected adults and children 12 years or older.
For prevention purposes, the drug should be used along with other prevention methods, the FDA said in a press statement, such as safe sex practices, risk reduction counseling, and regular HIV testing.
With the results from the two double-blind randomized controlled trials showing good evidence for prophylaxis, this is another step in the right direction towards HIV infection control.